Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

Movement Disorders : Official Journal of the Movement Disorder Society
R KatzenschlagerA J Lees

Abstract

Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug-induced dyskinesias in Parkinson's disease (PD). We prospectively assessed the antidyskinetic effect of continuous SC apomorphine therapy using subjective and objective measures, and sought to determine whether any observed dyskinesia reduction could be corroborated using single-dose dopaminergic challenges. Twelve PD patients with on-off fluctuations and disabling dyskinesias who were scheduled to start apomorphine pump treatment underwent acute levodopa and apomorphine challenges at baseline and 6 months later. Video recordings involving motor tasks were rated blindly by two independent raters using modified AIMS and Goetz dyskinesia scales. At 6 months, mean apomorphine dose was 75.2 mg per day and the mean L-dopa dose had been reduced by 55%. Daily off time in patients' diaries was reduced by 38% (2.4 hours). The L-dopa challenges showed a reduction of 44% in AIMS and 40% in Goetz scores (both P < 0.01). Apomorphine challenges showed a reduction of 39% in AIMS and 36% in Goetz scores (both P < 0.01). Patients' self-assessment scores reflected these significant changes. Dyskinesia improvement correlate...Continue Reading

References

Feb 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·J P FrankelG M Stern
Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·W R Gibb, A J Lees
Feb 20, 1988·Lancet·C M StibeG M Stern
Jul 1, 1988·Annals of Neurology·J I SageR C Duvoisin
Jul 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·C G GoetzE E Dorflinger
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·A J HughesG M Stern
Jun 1, 1994·Clinical Neuropharmacology·C ColosimoA Albanese
May 15, 1998·The British Journal of Dermatology·K M AclandP M Dowd
Oct 15, 1998·The New England Journal of Medicine·P LimousinA L Benabid
Nov 12, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·K PietzP Odin
Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·F DurifY Agid
Jan 25, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·A J MansonA J Lees
Sep 20, 2000·Neurology·A J MansonA J Lees
Oct 29, 2000·Trends in Neurosciences·J G NuttF Stocchi
Oct 29, 2000·Trends in Neurosciences·W OlanowO Rascol
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Aug 7, 2001·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·F StocchiS Ruggieri
Sep 29, 2001·The New England Journal of Medicine·UNKNOWN Deep-Brain Stimulation for Parkinson's Disease Study GroupA E Lang
Feb 9, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Petr KanovskýVladimír Znojil
Feb 13, 2002·Neurology·François J G VingerhoetsJ Ghika
Sep 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Simon G ParkinTipu Z Aziz
Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Alice J MansonAndrew J Lees
Jan 9, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Noël L W KeijsersStan C A M Gielen
Jun 5, 2003·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
May 22, 2007·Acta Neurologica Scandinavica·K SikkS-M Aquilonius

❮ Previous
Next ❯

Citations

Apr 21, 2007·Current Treatment Options in Neurology·Jayaraman Rao
Nov 19, 2008·Journal of Neurology·Francesca Del Sorbo, Alberto Albanese
Nov 26, 2010·Journal of Neurology·Angelo AntoniniMauro Plebani
May 29, 2008·Journal of Neural Transmission·S LalA Montoya
Mar 5, 2013·Journal of Neural Transmission·K Ray ChaudhuriKapil D Sethi
Mar 22, 2013·CNS Drugs·Fabienne Sprenger, Werner Poewe
Feb 5, 2013·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Jose-Alberto PalmaJorge Iriarte
Aug 26, 2006·Nature Clinical Practice. Neurology·C Warren OlanowFabrizio Stocchi
Oct 4, 2006·Nature Reviews. Drug Discovery·Anthony H V SchapiraGiora Davidai
Dec 14, 2011·The Neurologist·Maria Cruz Rodriguez-OrozOriol de Fabregues
Apr 3, 2008·Clinical Neuropharmacology·Mark Stacy, Andrew Galbreath
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Nov 29, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M Steiger
Jun 8, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A E EliaA Albanese
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
Sep 21, 2010·Clinical Interventions in Aging·Werner PoeweFrançois Vingerhoets
Oct 12, 2010·CNS Drugs·Santiago Perez-Lloret, Olivier Rascol
Dec 18, 2013·Journal of Neural Transmission·Dusan RoncevicHoracio Kaufmann
Aug 7, 2014·Neurodegenerative Disease Management·Tove Henriksen
May 1, 2009·Journal of Movement Disorders·Angelo Antonini
May 1, 2009·Journal of Movement Disorders·Heinz Reichmann
Oct 6, 2012·Journal of Medical Economics·Francesc ValldeoriolaUNKNOWN Workgroup of the SCOPE study
Jun 6, 2009·Expert Review of Neurotherapeutics·Angelo Antonini, Eduardo Tolosa
Feb 10, 2006·Expert Review of Neurotherapeutics·Ubaldo Bonuccelli, Nicola Pavese
Oct 18, 2007·Expert Review of Neurotherapeutics·Ubaldo Bonuccelli, Nicola Pavese
Mar 6, 2007·Expert Opinion on Drug Delivery·Y Naidu, K Ray Chaudhuri
Apr 15, 2009·Expert Opinion on Pharmacotherapy·Steven A Gunzler
Apr 23, 2009·Expert Opinion on Drug Delivery·Antonio Di StefanoLaura Serafina Cerasa
Dec 10, 2015·Expert Opinion on Drug Safety·Roberto CeravoloUbaldo Bonuccelli
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Ihtsham Ul HaqHubert H Fernandez
Mar 8, 2008·Expert Opinion on Drug Safety·Ubaldo Bonuccelli, Roberto Ceravolo
Feb 5, 2009·Brain Injury : [BI]·Esteban A FridmanRoss Zafonte

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.